Thrombotic complications following the administration of high-dose prothrombin complex concentrate for acute warfarin reversal

American Journal of Emergency Medicine

Volumn 34, Issue 8, 2016, Pages 1736.e1-1736.e3

  Zemrak, Wesley R ^a   Kelley, Erin ^a   Kovacic, Nicole L ^a   Mooney, Deirdre M ^a   Morris, Jane G ^a   MacVane, Casey Z ^a   Rosenblatt, Jeffrey A ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FRESH FROZEN PLASMA; OMEPRAZOLE; PANTOPRAZOLE; PROTHROMBIN COMPLEX; SODIUM CHLORIDE; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX CONCENTRATES;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ARTICLE; ATRIAL FIBRILLATION; BARE METAL STENT; BLEEDING; BLOATING; BRAIN INFARCTION; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COUGHING; DIARRHEA; DIVERTICULOSIS; DIZZINESS; DRUG MEGADOSE; DUAL ANTIPLATELET THERAPY; DUODENUM ULCER; DYSARTHRIA; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; ESOPHAGOGASTRODUODENOSCOPY; FALLING; FATIGUE; FEMALE; GASTROINTESTINAL CLIP; GAZE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEMIPARESIS; HUMAN; HYPERTENSION; HYPOKINESIA; HYPOXIA; LUNG EMBOLISM; MALE; MIDDLE AGED; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLOR; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PLASMA TRANSFUSION; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RESUSCITATION; SIDE EFFECT; ST SEGMENT ELEVATION; STENT THROMBOSIS; STOMACH ULCER; THORAX PAIN; THROMBOSIS; VOMITING; WEAKNESS; CHEMICALLY INDUCED; CORONARY THROMBOSIS; FEMORAL VEIN; GASTROINTESTINAL HEMORRHAGE; STROKE; VENOUS THROMBOSIS; VERY ELDERLY;

AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CORONARY THROMBOSIS; FEMALE; FEMORAL VEIN; GASTROINTESTINAL HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; STROKE; THROMBOSIS; VENOUS THROMBOSIS; WARFARIN;

EID: 85015602885     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2015.12.069     Document Type: Article

References (14)

1. [1] Holbrook, A., Schulman, S., Witt, D.M., Vandvik, P.O., Fish, J., Kovacs, M.J., et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl. (2012), e152S–e154S.
2. [2] Tran, H.A., Chunilal, S.D., Harper, P.L., Tran, H., Wood, E.M., Gallus, A.S., et al. An update of consensus guidelines for warfarin reversal. Med J Aust 198:4 (2013), 198–199.
3. [3] Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., et al. Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 154:3 (2011), 311–324.
4. [4] Goldstein, J.N., Refaai, M.A., Milling, T.J., Lewis, B., Goldberg-Alberts, R., Hug, B.A., et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 385:9982 (2015), 2077–2087.
5. [5] Pierce LR. Clinical review memo—Kcentra. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM352573.pdf2013.
6. [6] Sarode, R., Milling, T.J. Jr., Refaai, M.A., Mangione, A., Schneider, A., Durn, B.L., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:11 (2013), 1234–1243.
7. [7] Kcentra [prescribing information]. 2014, CSL Behring GmbH, Marburg, Germany.
8. [8] Milling, T.J. Jr., Refaai, M.A., Goldstein, J.N., Schneider, A., Omert, L., Harman, A., et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med 67:1 (2016), 96–105.
9. [9] Junagade, P., Grace, R., Gover, P., Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology 12:5 (2007), 439–440.
10. [10] Khorsand, N., Veeger, N.J., Muller, M., Overdiek, J.W., Huisman, W., van Hest, R.M., et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Transfus Med 21:2 (2011), 116–123.
11. [11] Khorsand, N., Veeger, N.J., van Hest, R.M., Ypma, P.F., Heidt, J., Meijer, K., An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 97:10 (2012), 1501–1506.
12. [12] van Aart, L., Eijkhout, H.W., Kamphuis, J.S., Dam, M., Schattenkerk, M.E., Schouten, T.J., et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118:3 (2006), 313–320.
13. [13] Varga, C., Al-Touri, S., Papadoukakis, S., Caplan, S., Kahn, S., Blostein, M., The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. Transfusion 53:7 (2013), 1451–1458 [quiz 0].
14. [14] Yasaka, M., Sakata, T., Naritomi, H., Minematsu, K., Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 115:6 (2005), 455–459.